OMEGAVEN AND PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS

Omegaven 和肠外营养相关的胆汁淤积

• 批准号: 8167144
• 负责人: Kara Lynne Calkins
• 金额: $ 0.07万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167144
• 关键词: Cholestasis; Computer Retrieval of Information on Scientific Projects Database; Fish Oils; Funding; Grant; Institution; Intravenous; Liver diseases; Parenteral Nutrition; Pilot Projects; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The specific aim of this pilot study is to investigate if intravenous (IV) fish oil (FO), commercially available as Omegaven? (Fresenius Kabi), at 1 gm/kg/d for no longer than 24 weeks, will safely reverse or ameliorate liver disease in 15 subjects with PNAC

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项试验研究的具体目的是研究静脉注射（IV）鱼油（FO）是否以omegaven的商业使用？ （Fresenius Kabi），在1克/kg/d的1克/d不超过24周，将在15名患有PNAC的受试者中安全逆转或改善肝病